A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
-
- STATUS
- Not Recruiting
Summary
The first purpose is to test the safety of the investigational medicine at different dose levels. We want to find out what effects, good and/or bad, it has on your type of cancer. The second purpose of this study is to measure the levels of the investigational medicine in your blood at different times. The third purpose is to see whether the investigational medicine has any effect in the control of cancer.
Description
The purpose of this study is to examine the safety and PK of ASG-22CE administered once weekly for 3 weeks of every 4 week cycle as monotherapy in subjects with metastatic urothelial cancer and other malignant solid tumors that express Nectin-4.
Details
| Condition | ovarian cancer,fallopian tube cancer,non-small cell lung cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX7887 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.